How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...
Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results